What is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the thymus gland. It plays a crucial role in immune system development and function, particularly in T-cell maturation and function.
Tα1 is approved in over 35 countries for conditions including hepatitis B, hepatitis C, and as an immune adjuvant. It’s one of the most clinically validated immune-modulating peptides available.
The 10mg vial provides 3-6 doses at typical research amounts.
Quick Reference
| Parameter | Value |
|---|---|
| Peptide Amount | 10mg |
| Recommended BAC Water | 2mL |
| Resulting Concentration | 5mg/mL |
| Typical Research Dose | 1.6-3.2mg |
| Frequency | 2-3x weekly |
| Research Duration | 4-12 weeks |
Reconstitution Guide
Concentration Calculations
2mL of BAC water is the practical choice here: it keeps the working concentration at a comfortable 5mg/mL, so typical doses land in the mid-range of a U-100 syringe rather than in the first few units.
With 10mg in 2mL BAC water:
- Concentration: 5mg/mL = 5000mcg/mL
- Per unit (U-100): 50mcg per unit
Using 1mL instead would give 10mg/mL (100mcg per unit), which halves every draw volume below — workable, but less forgiving on small measurements.
Dosage Protocol
Common Dose Calculations
| Desired Dose | Draw Volume | Syringe Units |
|---|---|---|
| 1.6mg | 0.32mL | 32 units |
| 2mg | 0.40mL | 40 units |
| 2.5mg | 0.50mL | 50 units |
| 3.2mg | 0.64mL | 64 units |
Doses Per Vial
| Dose | Doses Per Vial |
|---|---|
| 1.6mg | ~6 doses |
| 2.5mg | 4 doses |
| 3.2mg | ~3 doses |
| 5mg | 2 doses |
Suggested Protocols
Protocol A: Standard Immune Support
- Dose: 1.6mg
- Frequency: 2x weekly
- Duration: 4-12 weeks
Protocol B: Enhanced
- Dose: 3.2mg
- Frequency: 2x weekly
- Duration: 4-8 weeks
At 3.2mg twice weekly, a single 10mg vial covers a little over one week, so the reconstituted material is used well inside the 3-4 week window.
Storage Requirements
| Form | Temperature | Duration |
|---|---|---|
| Lyophilized | -20°C | 2+ years |
| Reconstituted | 2-8°C | 3-4 weeks |
Research Considerations
Mechanism of Action
- T-cell modulation — Enhances T-cell function
- Dendritic cell activation — Antigen presentation
- Cytokine regulation — Balances immune response
- NK cell enhancement — Natural killer cell activity
Clinical Validation
Approved/studied for:
- Hepatitis B and C
- Immune deficiency
- Cancer adjunct therapy
- Vaccine enhancement
- Sepsis
Thymosin Alpha-1 vs Other Immune Peptides
| Factor | Thymosin Alpha-1 | LL-37 |
|---|---|---|
| Primary action | T-cell modulation | Antimicrobial |
| Clinical approval | 35+ countries | Research phase |
| Best for | Immune modulation | Infection research |
Sourcing for Research
Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.